1. Home
  2. VRDN

as 03-28-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medical Specialities

Nasdaq

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Founded: 2006 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.6B IPO Year: N/A
Target Price: $36.44 AVG Volume (30 days): 771.2K
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.07 EPS Growth: N/A
52 Week Low/High: $11.40 - $27.20 Next Earning Date: 05-07-2025
Revenue: $302,000 Revenue Growth: -3.82%
Revenue Growth (this year): -23.51% Revenue Growth (next year): 17629.40%

VRDN Daily Stock ML Predictions

Share on Social Networks: